The Baddi facility was inspected by the United States Food and Drug Administration (USFDA) from February 17 to 21, 2020, Alkem Laboratories said in a filing to BSE.
The USFDA has now issued an EIR for the manufacturing facility, it added.
On February 21, the company in a regulatory filing had said USFDA had issued a Form 483 with two observations at the end of the inspection of the facility.
It had said it shall put together a detailed response with adequate corrective and preventive measures to address the USFDA observations.
Shares of Alkem Laboratories were trading at Rs 2,468.40 per scrip on BSE, up 3.62 per cent from its previous close. AKT ANSANS